You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Alzheimer’s drug designed using Exscientia’s AI technology enters clinic

An Alzheimer’s disease drug candidate designed using Exscientia’s artificial intelligence (AI) technology has entered Phase I clinical testing, the company announced yesterday.